Blocking the PD-1/PD-L1 interaction through therapeutic monoclonal antibodies, known as immune checkpoint inhibitors, reduces immune suppression and generates the activity of tumor-specific T lymphocytes. This evidence concerns the gene PDCD1 and neoplasm.